FDU-PB-22
Synthetic cannabinoid of the indole-3-carboxylate family, classified as a narcotic in France.
C₂₆H₁₈FNO₂
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Data sheet
Names
- IUPAC name
- naphthalen-1-yl 1-[(4-fluorophenyl)methyl]indole-3-carboxylate
- Other names
- naphthalen-1-yl 1-(4-fluorobenzyl)-1h-indole-3-carboxylate
Identifiers
- Formula
- C₂₆H₁₈FNO₂
- Molar mass
- 395.40 g/mol
- CAS
- 1883284-94-3
- PubChem CID
- 119025888(new tab)
- InChIKey
- RCEKSVIFQKKFLS-UHFFFAOYSA-N
Class
- Family
- Synthetic cannabinoid (SCRA)
Updated on
Receptors and activity
- CB1Agonist20 out of 100
aucune constante d'affinité publiée dans les sources consultées pour le FDU-PB-22 (classe des carboxylates d'indole : agonistes selon Hill et coll., 2018)
- CB2Agonist20 out of 100
aucune constante d'affinité publiée dans les sources consultées pour le FDU-PB-22 (classe des carboxylates d'indole : agonistes selon Hill et coll., 2018)
Subjective signature
- Calm
- 5 out of 100
- Relaxation of body and mind; reduced mental noise without marked drowsiness.
- Clarity
- 5 out of 100
- Sustained attention and clear thinking; functional lucidity, not euphoria.
- High
- 10 out of 100
- Euphoria and sensory intensity; altered perception of time and space.
- Appetite
- 10 out of 100
- Stimulation of hunger and of taste appreciation (the “munchies” effect).
- Sleep
- 10 out of 100
- Sedative effect: aids sleep onset and the continuity of deep sleep.
Pharmacology
FDU-PB-22 is a synthetic cannabinoid of the indole-3-carboxylate family, sharing its structural family with PB-22. It was detected in 2014 in herbal mixtures in Japan, Russia and Germany (Diao et al., 2016). No affinity constant for CB1 or CB2 is published for this molecule in the sources consulted. The available data concern mainly its metabolism: its half-life in human liver microsomes is 12.4 minutes, and its hydrolysis yields an indole-3-carboxylic acid (FBI-COOH), and this acid and its hydroxylated derivative are recommended as urinary markers. No clinical series specific to FDU-PB-22 was found in the sources consulted, so its toxicity profile remains poorly documented.
Key sources.
- Diao et coll., métabolisme in vitro et in vivo du FDU-PB-22 et du FUB-PB-22, AAPS Journal, 2016 (new tab)PMID 26810398
- Jones et coll., glucuronidation du FDU-PB-22 par les UGT hépatiques, Xenobiotica, 2019 (new tab)PMID 30739533
- Banister et coll., effets du fluor de bioisostérie sur huit cannabinoïdes de synthèse dont le PB-22 et le 5F-PB-22, ACS Chemical Neuroscience, 2015 (new tab)PMID 25921407
- Hill et coll., toxicité humaine des carboxylates d'indole et d'indazole de synthèse, Clinical Chemistry, 2018 (new tab)PMID 29038156
- Liste consolidée des substances classées comme stupéfiants (ANSM, mise à jour du 16 février 2026), annexe IV, bloc « Dérivés du 3-carboxylate indole » (new tab)
- Liste verte de l'OICS, 36e édition (2025), absence du FDU-PB-22 (new tab)
- Fiche PubChem du FDU-PB-22 (CID 119025888) (new tab)
History
- Source
- Synthetic molecule, described as such in the analytical and toxicological literature. No source consulted reports it in a plant or a living organism. It has been found in herbal mixtures, according to the 2014 reports cited by Diao et al. (2016).
Origin (pharmaceutical research → illicit market)
No biosynthetic route: FDU-PB-22 is a synthetic compound with no known natural equivalent. It belongs to the class of indole-3-carboxylic acid esters, whose indole nitrogen carries a 4-fluorobenzyl group and whose ester is linked to 1-naphthol.
Legal framework
- European Union
No harmonised control measure at Union level was found in the sources consulted for FDU-PB-22; control therefore falls under the national legislation of the member states. It is also absent from the INCB Green List (36th edition, 2025), which reproduces the schedules of the 1971 Convention.
- France
Classified as a narcotic in France and cited by name. FDU-PB-22 appears in annex IV of the consolidated list of narcotics (updated 16 February 2026), within the block « 3-carboxylate indole derivatives », where the « Notamment » list cites « FDU-PB-22 ou naphthalen-1-yl 1-[(4-fluorophenyl) methyl]-1H-indole-3-carboxylate ». Its structure also meets each condition of this generic family definition (halobenzyl group on the indole nitrogen, indole core substituted or not, 1-naphthalenyl group on the carboxylate oxygen), but the classification rests on the citation by name.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
References
- Diao et coll., métabolisme in vitro et in vivo du FDU-PB-22 et du FUB-PB-22, AAPS Journal, 2016 (new tab)PMID 26810398
- Jones et coll., glucuronidation du FDU-PB-22 par les UGT hépatiques, Xenobiotica, 2019 (new tab)PMID 30739533
- Banister et coll., effets du fluor de bioisostérie sur huit cannabinoïdes de synthèse dont le PB-22 et le 5F-PB-22, ACS Chemical Neuroscience, 2015 (new tab)PMID 25921407
- Hill et coll., toxicité humaine des carboxylates d'indole et d'indazole de synthèse, Clinical Chemistry, 2018 (new tab)PMID 29038156
- Liste consolidée des substances classées comme stupéfiants (ANSM, mise à jour du 16 février 2026), annexe IV, bloc « Dérivés du 3-carboxylate indole » (new tab)
- Liste verte de l'OICS, 36e édition (2025), absence du FDU-PB-22 (new tab)
- Fiche PubChem du FDU-PB-22 (CID 119025888) (new tab)
Structured data
- SMILES
- C1=CC=C2C(=C1)C=CC=C2OC(=O)C3=CN(C4=CC=CC=C43)CC5=CC=C(C=C5)F
- InChIKey
- RCEKSVIFQKKFLS-UHFFFAOYSA-N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.